Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28721100 | 1.00 | CALCRL (0.42) | CALCRLRAMP1 | |
| SCHEMBL29518096 | 1.00 | CALCRL (0.42) | CALCRLRAMP1 | |
| SCHEMBL31126018 | 1.00 | CALCRL (0.42) | CALCRLRAMP1 | |
| SCHEMBL22796662 | 0.89 | CALCRL (0.39) | CALCRLRAMP1 | |
| SCHEMBL29517842 | 0.89 | CALCRL (0.39) | CALCRLRAMP1 | |
| SCHEMBL22796621 | 0.87 | IP6K1 (0.39) | CALCRLRAMP1 | |
| SCHEMBL22796544 | 0.87 | IP6K1 (0.39) | CALCRLRAMP1 | |
| SCHEMBL31084963 | 0.87 | IP6K1 (0.39) | CALCRLRAMP1 | |
| SCHEMBL29996255 | 0.87 | IP6K1 (0.39) | CALCRLRAMP1 | |
| SCHEMBL29517785 | 0.87 | IP6K1 (0.39) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| CN-114245797-B | CGRP antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-114245798-B | CGRP antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-08-11 | — | — | US | disclosed |
| WO-2020249970-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249969-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CALCRL 1/4885RAMP1 49/4885 |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CALCRL 1/4885RAMP1 49/4885 |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 67/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | CALCRL 1/4885RAMP1 49/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.